about
Evaluation of 18F-nifene binding to α4β2 nicotinic receptors in the rat brain using microPET imaging5-HT1A sex based differences in Bmax, in vivo KD, and BPND in the nonhuman primateNicotinic acetylcholine receptors in rat forebrain that bind ¹⁸F-nifene: relating PET imaging, autoradiography, and behavior.Comparative assessment of (18) F-Mefway as a serotonin 5-HT1A receptor PET imaging agent across species: Rodents, nonhuman primates, and humansClassification of Therapeutic and Experimental Drugs for Brown Adipose Tissue Activation: Potential Treatment Strategies for Diabetes and ObesityPerformance evaluation of an Inveon PET preclinical scanner.Brain and Brown Adipose Tissue Metabolism in Transgenic Tg2576 Mice Models of Alzheimer Disease Assessed Using 18F-FDG PET Imaging.In vivo kinetics of [F-18]MEFWAY: a comparison with [C-11]WAY100635 and [F-18]MPPF in the nonhuman primate.An in vivo comparison of cis- and trans-[18F]mefway in the nonhuman primateMeasurement of 5-HT(1A) receptor density and in-vivo binding parameters of [(18)F]mefway in the nonhuman primate.Evaluation of serotonin 5-HT(1A) receptors in rodent models using [¹⁸F]mefway PET.First-in-human evaluation of 18F-mefway, a PET radioligand specific to serotonin-1A receptors.Imaging pancreas in healthy and diabetic rodent model using [18F]fallypride positron emission tomography/computed tomography.PET imaging of α4β2* nicotinic acetylcholine receptors: quantitative analysis of 18F-nifene kinetics in the nonhuman primate.Nicotinic α4β2 receptor imaging agents. Part IV. Synthesis and biological evaluation of 3-(2-(S)-3,4-dehydropyrrolinyl methoxy)-5-(3'-¹⁸F-fluoropropyl)pyridine (¹⁸F-Nifrolene) using PET.Measuring α4β2* nicotinic acetylcholine receptor density in vivo with [(18)F]nifene PET in the nonhuman primateAdrenergic pathway activation enhances brown adipose tissue metabolism: a [¹⁸F]FDG PET/CT study in mice.18F-Fluorodeoxyglycosylamines: Maillard reaction of 18F-fluorodeoxyglucose with biological amines.18F-desmethoxyfallypride: a fluorine-18 labeled radiotracer with properties similar to carbon-11 raclopride for PET imaging studies of dopamine D2 receptors.Enhancement of 18F-fluorodeoxyglucose metabolism in rat brain frontal cortex using a β3 adrenoceptor agonistNicotinic alpha4beta2 receptor imaging agents: part II. Synthesis and biological evaluation of 2-[18F]fluoro-3-[2-((S)-3-pyrrolinyl)methoxy]pyridine (18F-nifene) in rodents and imaging by PET in nonhuman primate.Effect of acetylcholinesterase inhibitors on the binding of nicotinic alpha4beta2 receptor PET radiotracer, (18)F-nifene: A measure of acetylcholine competition.Striatal and extrastriatal microPET imaging of D2/D3 dopamine receptors in rat brain with [¹⁸F]fallypride and [¹⁸F]desmethoxyfallyprideSynthesis and Evaluation of Mefway Analogs as Ligands for Serotonin 5HT1A ReceptorsNicotinic α4β2 receptor imaging agents. Part III. Synthesis and biological evaluation of 3-(2-(S)-azetidinylmethoxy)-5-(3'-18F-fluoropropyl)pyridine (18F-nifzetidine).(18)F-Fluorodeoxyglucamines: Reductive amination of hydrophilic (18)F-fluoro-2-deoxyglucose with lipophilic amines for the development of potential PET imaging agents.Dopamine D3 receptor binding of (18)F-fallypride: Evaluation using in vitro and in vivo PET imaging studies.A progressive translational mouse model of human valosin-containing protein disease: the VCP(R155H/+) mouseEvaluation of [18F]Nifene biodistribution and dosimetry based on whole-body PET imaging of mice.[11C]cyclopropyl-FLB 457: a PET radioligand for low densities of dopamine D2 receptors11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas.Specific α4β2 nicotinic acetylcholine receptor binding of [F-18]nifene in the rhesus monkeySynthesis and biological evaluation of 18F-Norfallypride in the rodent brain using PET imaging.Targeting presynaptic norepinephrine transporter in brown adipose tissue: a novel imaging approach and potential treatment for diabetes and obesity.¹²⁴I-Epidepride: a PET radiotracer for extended imaging of dopamine D2/D3 receptors.The multiple faces of valosin-containing protein-associated diseases: inclusion body myopathy with Paget's disease of bone, frontotemporal dementia, and amyotrophic lateral sclerosis.A comparative study on the uptake and incorporation of radiolabeled methionine, choline and fluorodeoxyglucose in human astrocytoma.Spinal cord dopamine D2/D3 receptors: in vivo and ex vivo imaging in the rat using (18)F/(11)C-fallypridePreliminary evaluation of β3-adrenoceptor agonist-induced 18F-FDG metabolic activity of brown adipose tissue in obese Zucker rat.Synthesis and evaluation of (S)-[(18)F]fesetron in the rat brain as a potential PET imaging agent for serotonin 5-HT3 receptors
P50
Q21195727-6A666382-83F7-420B-AED1-694AD6408D70Q30432949-1F010BC4-D474-4319-89E6-62DEDCBDDEFFQ30455122-DEB13351-F443-4106-8BF7-194FEE75807EQ30724808-8A34B84D-924A-4AEE-869B-CB8E14FB0DC4Q33659194-405A0993-1E37-4C49-BC4C-330651A12743Q33728565-454C8D74-E8E2-4B86-8CEE-4713F67F086DQ33795465-2EC453B3-A5B4-494C-9F5A-85316DFC88B7Q34026498-912321E4-BC05-4D76-84E4-5A1ED88C7D2BQ34027588-E35DF0B9-9B65-47DC-B782-E504A329AC2EQ34031349-945735E1-FCEC-4ACB-9459-A9D18E0487E5Q34036060-DE15C1CF-6C0C-4AB1-9BAA-E8C39B86E787Q34042581-5D01BB25-2EAF-4C95-88C4-BBA0098969D4Q34283950-906BC483-FC4F-47E2-9748-9E312D11037FQ34291685-AD1C7A67-F14B-4F6C-96AE-23D8AE08C1C7Q34310935-4DC5AFEB-51E2-4150-A2B8-08A4F524C806Q34363819-463590D6-CC6D-43F0-9B94-C745D5A59DC1Q34375039-7B135685-EAEF-4CE0-BC95-7915F342D03FQ34391111-22418F36-5BA2-4C19-AF91-DCA0C9AF98C0Q34392904-5BD4AEFD-0A0C-4E5F-8601-02F02FC0A487Q34445014-7A8535E9-D62C-4811-BD37-CD7D6C54FD52Q34516347-423FEADA-0654-4038-8121-BA76D52A0674Q34577160-361C7699-73E4-4E4E-8366-5D431C27B393Q35024059-B671ECA0-C656-450F-83F6-09336D5B0981Q35146456-D0FE1D5A-15FD-4525-9FCE-670F14C107FEQ35552411-58CE8753-00B9-45C6-A9BD-3E42C2F6D94CQ35747666-C925F958-2467-4F69-B2AA-6369D0189AC2Q36219773-151FE1E2-0029-449D-AEE6-42F9F005C144Q36565507-19571EE4-270B-4168-8760-F38E8EACE911Q36569391-03D53605-492D-4EB2-8CBA-F7798C5A077FQ36865865-4BDB79F5-5334-4AD0-BB34-6DADCAABFF9EQ36980379-C434720F-CE44-4B0E-94DB-4BB80B2FA788Q36994843-D9350DE9-CE77-420F-AB83-21EA45A1C4EFQ37117235-0BE03B63-0FE8-4F76-A873-C15E94D40C68Q37256662-D128BF07-2788-4061-88EE-796A27BE2B16Q37732426-1DBD1DF7-61B8-436C-A4CF-E0560BAF9BF5Q37926529-B5F227AD-907B-41C3-A062-856713F1E5DDQ40627611-37E08B58-2560-4DEB-9B4E-684B97E5DCA4Q41790133-70F8A389-25A7-4849-A454-0678B917B71BQ41811048-E83171CD-1FF0-47BE-8588-80BBA752020BQ42205380-4478D753-A0AB-48CF-8CFC-654D2CB79B03
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Jogeshwar Mukherjee
@ast
Jogeshwar Mukherjee
@en
Jogeshwar Mukherjee
@es
Jogeshwar Mukherjee
@nl
Jogeshwar Mukherjee
@sl
type
label
Jogeshwar Mukherjee
@ast
Jogeshwar Mukherjee
@en
Jogeshwar Mukherjee
@es
Jogeshwar Mukherjee
@nl
Jogeshwar Mukherjee
@sl
altLabel
Jogesh Mukherjee
@en
prefLabel
Jogeshwar Mukherjee
@ast
Jogeshwar Mukherjee
@en
Jogeshwar Mukherjee
@es
Jogeshwar Mukherjee
@nl
Jogeshwar Mukherjee
@sl
P1053
O-1320-2013
P106
P1153
7102915216
P2798
P31
P3829
P496
0000-0003-1009-877X